Rationale? Sorry but your "detailed rationale" is a continued fail.
Novartis spoke with $ after a period of negotiation, with a rank of 3rd to 6th largest pharmaceutical company (depending on ranking method) in the world during 2020 and significant research resources that is sufficient proof for me that your point of view is of nil value.
You are the one who has no sentiment and nil position and continually expressed doubts on economic viability of treatment. You continue so desperately to need answers, I simply provide a resource to assuage your concerns over price positioning.
MSB Trading 2021 - paradigm shift, page-224
-
- There are more pages in this discussion • 9,987 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |